adult
Conditions
Interventions
Skin autofluorescence (SAF) was measured at the first visit and at 6 months.
Patients with higher than normal skin autofluorescence (SAF) were included in the treatment group. In the treatment group
Sponsors
Aoyama Clinic, Medical Corporation Seiyukai
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Selection criteria Patients over 20 years old at the time of consent Setting basis 1. For those who can show the free will of patients and their families with sufficient understanding 2. Set for accurate effectiveness assessment
Exclusion criteria
Exclusion criteria: Exclusion criteria Under 120 years old 2 Patients who had difficulty continuing oral administration 3 Patients who had difficulty in continuing medical examinations 4 Patients who could not follow the blood test 5 Patients with a history of allergies to legumes because legumes are legumes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skin autofluorescence (SAF), which can evaluate advanced glycation end products non-invasively, is used to evaluate glycation, and Ogi powder is administered to patients with high SAF values to evaluate the therapeutic effect. | — |
Countries
Japan
Contacts
Public ContactShigeo Aoyama
Medical Corporation Seiyukai Aoyama Clinic
Outcome results
None listed